We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
-9.88%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.56B
AUM Growth
+$143M
Cap. Flow
+$317M
Cap. Flow %
20.31%
Top 10 Hldgs %
50.44%
Holding
68
New
13
Increased
28
Reduced
8
Closed
16

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$70.6M
2
FATE icon
Fate Therapeutics
FATE
+$61.3M
3
AGEN
Agenus
AGEN
+$38.5M
4
BCYC
Bicycle Therapeutics
BCYC
+$35.3M
5
NVCR icon
NovoCure
NVCR
+$33.1M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$23.8M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$17.1M
3
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$13.2M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$11.9M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.24%
2 Real Estate 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TCDA
26
DELISTED
Tricida, Inc. Common Stock
TCDA
$21.8M 1.4%
2,652,693
+317,550
+14% +$2.87M
VRDN icon
27
Viridian Therapeutics
VRDN
$2.09B
$21.6M 1.39%
1,170,290
-166,400
-12% -$3.2M
SLN
28
Silence Therapeutics
SLN
$495M
$18.1M 1.16%
951,580
+782
+0.1% +$15.6K
DNTH icon
29
Dianthus Therapeutics
DNTH
$5.84B
$15.5M 1%
334,938
+30,563
+10% +$1.67M
FMTX
30
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$15.4M 0.99%
+1,659,706
New +$17.7M
FULC icon
31
Fulcrum Therapeutics
FULC
$273M
$15.4M 0.99%
650,000
-100,000
-13% -$1.42M
ENTA icon
32
Enanta Pharmaceuticals
ENTA
$366M
$14.1M 0.91%
+198,730
New +$12.9M
ANAB icon
33
AnaptysBio
ANAB
$1.58B
$13.8M 0.89%
+558,782
New +$16.9M
GRTS
34
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$12.3M 0.79%
2,985,729
+1,213,928
+69% +$6.43M
IPSC icon
35
Century Therapeutics
IPSC
$364M
$11.7M 0.75%
926,469
+676,469
+271% +$8.96M
HOOK
36
DELISTED
HOOKIPA Pharma
HOOK
$11.5M 0.74%
+503,600
New +$9.03M
PASG icon
37
Passage Bio
PASG
$14.4M
$10.5M 0.67%
168,750
+7,900
+5% +$651K
ABOS icon
38
Acumen Pharmaceuticals
ABOS
$155M
$10.2M 0.65%
2,599,098
+666,058
+34% +$3.62M
RXDX
39
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$9.25M 0.59%
+245,000
New +$9.68M
GHRS icon
40
GH Research
GHRS
$1.93B
$9.13M 0.59%
499,400
– –
TNYA icon
41
Tenaya Therapeutics
TNYA
$161M
$6.44M 0.41%
546,923
-215,394
-28% -$2.61M
ASMB icon
42
Assembly Biosciences
ASMB
$498M
$6.18M 0.4%
250,000
– –
NUVB icon
43
Nuvation Bio
NUVB
$2.2B
$6.08M 0.39%
+1,155,492
New +$6.49M
ATYR
44
aTyr Pharma
ATYR
$47.6M
$5.5M 0.35%
1,028,515
-71,485
-6% -$405K
NKTR icon
45
CALL
Nektar Therapeutics
NKTR
$2.39B
$5.39M 0.35%
+66,667
New +$9.87M
PTGX icon
46
PUT
Protagonist Therapeutics
PTGX
$8.79B
$3.51M 0.23%
+148,300
New +$4.18M
RLMD icon
47
Relmada Therapeutics
RLMD
$557M
$2.76M 0.18%
+102,117
New +$2.11M
VIGL
48
DELISTED
Vigil Neuroscience
VIGL
$2.74M 0.18%
+389,141
New +$5.14M
NKTR icon
49
PUT
Nektar Therapeutics
NKTR
$2.39B
$2.69M 0.17%
33,333
– –
VERV
50
DELISTED
Verve Therapeutics
VERV
$2.33M 0.15%
102,342
-397,658
-80% -$11.4M
1
2
3

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Deep Track Capital held 68 positions worth $1.56B, up 10% from $1.42B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Deep Track Capital deployed $317M of net new capital in Q1 2022, opening 13 new positions and adding to 28 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 463,663 shares worth $75.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier, followed by Real Estate.

On the sell side, the largest reduction was Verve Therapeutics, an estimated $11.4M trimmed.

  • Deep Track Capital's largest Q1 2022 buy was Alnylam Pharmaceuticals: 463,663 shares worth $75.7M.
  • Deep Track Capital added most to Fate Therapeutics in Q1 2022, an estimated $61.3M increase.
  • Deep Track Capital's biggest Q1 2022 reduction was Verve Therapeutics, cutting an estimated $11.4M.
  • Deep Track Capital fully exited Avidity Biosciences in Q1 2022, selling an estimated $23.8M.
  • Deep Track Capital's ten largest holdings make up 50% of its $1.56B portfolio in Q1 2022.
  • Deep Track Capital opened 13 new positions and closed 16 in Q1 2022.
  • Deep Track Capital's portfolio value rose 10% quarter-over-quarter to $1.56B.

Based on Deep Track Capital's 13F filing for Q1 2022, filed 16 May 2022.